feedback

Course Director

Daniel J. DeAngelo, MD, PhD
Daniel J. DeAngelo, MD, PhD

Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty

Monika Brüggemann
Monika Brüggemann, MD, PhD

University Hospital Kiel
Kiel, Germany

Stephan A. Grupp
Stephan A. Grupp, MD, PhD

University of Pennsylvania Perelman School of Medicine
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Elias Jabbour
Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2016-Dec-28
Expiration Date:2017-Dec-27
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, leading experts offer key insights on the evolution of acute lymphoblastic leukemia (ALL) care, and how the present and future of patient management will change in its wake. The experts address important topics such as how minimal residual disease (MRD) monitoring will be integrated into the use of novel therapies, the impact of antibody-based approaches—including antibody–drug conjugates and bispecific agents—on patient care, and the emergence of other immunotherapy strategies, such as chimeric antigen receptor (CAR) T-cell therapy. Survey responses from patients on the emergence of this new generation of therapies, collected via a survey, are featured alongside the science-based presentations. This activity highlights the emerging science that may mark a new road in the care of patients with ALL, who may not benefit from standard chemotherapy, and a change in how optimal care is defined.

Upon completion of this activity, participants should be better able to:
  • Describe the mechanisms of novel immunotherapies and antibody-based treatments in ALL, including antibody–drug conjugates, bispecific agents, and other options
  • Cite clinical evidence on the efficacy of immunotherapy and antibody-based treatment in ALL, including in relapsed/refractory disease and other populations with unmet clinical needs
  • Integrate antibody therapy into the management of ALL patients with relapsed/refractory disease and other relevant treatment settings
  • Manage treatment-related toxicity in patients with ALL receiving antibody-based therapy
  • Identify patients with ALL eligible to receive novel treatments, including antibodies or immunotherapy, in the setting of a clinical trial

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, advanced practice oncology nurses, and other healthcare professionals involved in the care of patients with ALL.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 28, 2016 - December 27, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator
Daniel J. DeAngelo, MD, PhD
Director of Clinical and Translational Research, Adult Leukemia
Institute Physician
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen; ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty
Monika Brüggemann, MD, PhD
Department of Hematology
University Hospital Kiel
Kiel, Germany

Monika Brüggemann, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc. and ARIAD Pharmaceuticals, Inc.
Grant/Research Support from Amgen Inc. and Celgene Corporation.
Speakers Bureau participant with Amgen Inc. and F. Hoffmann-La Roche Ltd.

Stephan A. Grupp, MD, PhD
Novotny Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Director, Cancer Immunotherapy Frontier Program
Director of Translational Research
Fellowship Director
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Stephan A. Grupp, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Adaptimmune; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Novartis Pharmaceuticals Corporation.

Elias Jabbour, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Pfizer; and Teva Pharmaceuticals USA.
Grant/Research Support from ARIAD Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Teva Pharmaceuticals USA.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5995-17-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.